Viracta Therapeutics Closes Series D Financing

Viracta TherapeuticsViracta Therapeutics, Inc., a San Diego, CA-based precision oncology company targeting virus-associated malignancies, closed a Series D financing of undisclosed amount.

The round was led by Taiwania Capital Management with participation from existing investors. In conjunction with the financing, Michael Huang, Managing Partner at Taiwania Capital Management, joined Viracta’s Board of Directors.

Led by Ivor Royston, MD, President and Chief Executive Officer, Viracta is a precision oncology company targeting virus-associated malignancies. The company’s proprietary lead molecule, nanatinostat, is currently being evaluated as an oral combination therapy with valganciclovir in a Phase 2 clinical trial for Epstein-Barr virus positive lymphomas. Viracta is pursuing application of this Kick and Kill approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, and other virus-related cancers.

Proceeds from the financing are expected to be used to complete the Phase 2 study and subsequent initiation of registration studies, as well as for other general corporate purposes. Additionally, the company intends to pursue the application of its Kick and Kill approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, and other virus-related cancers.

FinSMEs

28/10/2019

Join the discussion